1Efficacy and safety evaluation of sintilimab in patients with advanced or metastatic non-squamous NSCLC. ClinicalTrials.gov identifier: NCT03607539. Updated February 16, 2021. Accessed June 11, 2021. https://www.clinicaltrials.gov/ct2/show/NCT03607539
2Yang Y, Wang Z, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020;15(10):1636-1646. https://doi.org/10.1016/j.jtho.2020.07.014
3Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, Bi M, Ren X, Zhou J, Li B, Song Y, Feng J, Li J, He Z, Zhou R, Li W, Lu Y, Zhou H, Wang S, Sun L, Puig O, Mancao C, Peng B, Fang W, Xu W, Zhang L. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. J Thorac Oncol. 2021 Aug 3:S1556-0864(21)02330-3. doi: 10.1016/j.jtho.2021.07.015. Epub ahead of print. PMID: 34358724.